CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	6 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
CASH FLOWS FROM OPERATING ACTIVITIES:
Net Income (Loss)	$ (514,092)	$ (63,121)
Adjustment to reconcile net income (loss) to net cash provided by (used in) operating activities
(Gain)/Loss on change in derivative liability	(1,180,067)	75,537
Stock compensation expense	936,000	0
Stock issued for services	145,941	0
Changes in Assets and Liabilities:
Prepaid expenses	0	3,805
Accounts payable	163,310	(42,942)
Other payable	1,590	0
License fees payable	(10,000)	0
Accrued expenses and interest on notes payable	32,999	(1,761)
Accrued payroll	23,290	0
Deferred Compensation	120,508	0
NET CASH PROVIDED BY (USED IN) OPERATING ACTIVITIES - CONTINUING OPERATIONS	(280,521)	(28,482)
NET CASH PROVIDED BY (USED IN) OPERATING ACTIVITIES - DISCONTINUED OPERATIONS	0	140,134
NET CASH (USED IN) PROVIDED BY OPERATIONS	(280,521)	111,652
CASH FLOWS FROM FINANCING ACTIVITIES:
Stock subscriptions received	295,000	0
Due to related party	6,628	0
Payments on related party promissory notes	0	(7,200)
Proceeds from a related party loan	25,000	0
Payments on related party loan payable	(24,287)	0
NET CASH PROVIDED BY (USED IN) FINANCING ACTIVITIES	302,341	(7,200)
NET INCREASE (DECREASE) IN CASH	21,820	104,452
CASH, BEGINNING OF PERIOD	178	7,964
CASH, END OF PERIOD	21,998	112,416
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION
Interest paid	1,386	4,840
Taxes paid	0	0
SUPPLEMENTAL DISCLOSURES OF NON CASH TRANSACTIONS
Accrued interest capitalized into convertible note	2,505	2,235
Shares issued for StemVax Acquisition – from stock payable	$ 6,375,000	$ 0